Genmab — September 2022
-
Asien: Efteråret starter med udsalg i Asien https://www.proinvestor.com/investornyt/873592/asien-efteraret-starter-med-udsalg-i-asien
-
Debatten om Mærsk: "køb billigt" eller "sælg billigt" kører derudaf. Værterne kommer også ind på Bavarian Nordics svingende aktiependul. Derudover diskuteres Jackson Hole, og den enorme effekt det har haft på investorerne. Der sluttes af med danske life-science-selskaber, og hvordan de skubber USD-boomet foran sig. Lyt til afsnit 133 af Investeringspodcasten med Hansen og Larsen her. https://www.proinvestor.com/boards/105797
-
Golden Cross Appears Before Genmab Investors
If history is any guide, there may be good fortune ahead for shares of
GENMAB
(NASDAQ:GMAB). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
WHAT TO KNOW:
Many traders use moving average crossover systems to make their decisions.
When a shorter-term average price crosses above a longer-term average price, it could mean the stock is trending higher. If the short-term average price crosses -
below the long-term average price, it means the trend is lower.
WHY IT'S IMPORTANT:
The 50-day and the 200-day simple moving averages are commonly used.The golden cross occurs when the 50-day crosses above the 200-day. This could mean the long-term trend is changing.
That just happened with Genmab, which is trading around $35.63 at publication time.
-
@Pensionisten. Tak for deling. Flot opjustering af Société Générale. Niveauet vil der altid være delte meninger om og man kan da undres over, at Société Générale finder +25 % på kursmålet i disse dage med stigende renter. Mon det alene er godkendelsen Tecvayli eller en erkendelse af, at virkeligheden er løbet fra det tidligere kursmål?
-
PharmCube
@pharmcube
·
30 aug.
Janssen's Class 1 new drug, teclistamab for injection, is to receive breakthrough therapy designation in #China for patients with r/r maultiple #myeloma who have received at least 3 lines of treatment. https://twitter.com/pharmcube/status/1564547202709536768 -
Mim8 data sees potential as once monthly treatment for haemophilia A https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/new-drug-development-approvals-regulatory-news/mim8-data-sees-potential-as-once-monthly-treatment-for-haemo/
-
Overview of the Mim8 FRONTIER clinical development program http://www.postersessiononline.eu/173580348_eu/congresos/WFH2022/aula/-PO_17_WFH2022.pdf
-
Aktier/Sydbank: Efteråret kan blive hedt https://www.proinvestor.com/investornyt/873657/aktier-sydbank-efteraret-kan-blive-hedt
-
ATP-aktiechef: Reduktion i danske aktier en nødvendighed - Mærsk ramt https://www.proinvestor.com/investornyt/873713/atp-aktiechef-reduktion-i-danske-aktier-en-nodvendighed-maersk-ramt
-
Børsen:
Novo Nordisk har købt det amerikanske biotekselskab Forma Therapeutics for en pris på 1,1 mia. dollar (8,2 mia. kr.), skriver selskabet i en børsmeddelelse. -
Kort video: .....update på Bavarian Nordic . Slutteligt fortæller Helge Larsen om overeksponering, og hvordan det i 2004 kostede ham dyrt. https://www.proinvestor.com/boards/105815
-
US renten tog lige +4,5 i dag og giver et godt skub til FX'en. Genmab kommer til at opjustere med yderligere ca. 300 mio. kr. på valutafronten når vi rammer 31/12. Det fordrer for gode lønforhøjelser i selskabet, så de ansatte kan sikres mod inflationen.
-
Completion of share buy-back program https://www.proinvestor.com/investornyt/873980/completion-of-share-buy-back-program
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind